The objective of this study is to evaluate the efficacy and safety of Pegasys in combination with Copegus given for 16 weeks versus 24 weeks in previously untreated patients with Chronic Hepatitis C virus Genotype 2 or 3.
Evaluation of the efficacy and safety of Pegasys in combination with Copegus given 16 weeks versus 24 weeks in previously untreated patients with Chronic Hepatitis C virus Genotype 2 or 3
– Chronic Hepatitis C
Treatment, Safety/Efficacy Study
Eligibility & Criteria
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both Criteria Inclusion Criteria:At least 18 years old Infected with Hepatitis C virus Genotype 2 or 3 Exclusion Criteria:Pregnant, breast-feeding or male partners of those who are pregnant Hepatitis C virus Genotype 1, 4, 5 or 6 Previously treated with interferon, pegylated interferon, ribavirin or viramidine at any previous time or any other systemic antiviral therapy or investigational drug less than or equal to 3 months prior to first dose of study drug. Exception: Patients with a limited (less than or equal to 7 day) course of acyclovir or valacyclovir for herpes more than 1 month prior to first dose of study drug are not excluded.
Adelaide, 5000, Australia; Recruiting Prahran, 3181, Australia; Recruiting HERSTON, 4029, Australia; Recruiting Kingswood, Australia; Recruiting Woollongabba, 4102, Australia; Recruiting